Immatics
Develops PRAME-focused cancer therapies with cell therapy and TCR bispecific programs.
$9.35
After-hours close−0.09 (−0.95%)
At close$9.44(+0.85%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 80.68%108.19M sharesInsiders 8.92%11.97M sharesOther 10.40%13.94M shares
Shares outstanding 134.10M · Float 112.20M · 83.7% free float
Institutions13F, as of Mar 31, 2026
85 holders · 108.19M shares · 15 new positions · 43 increased · 23 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 21.65M | 16.15% | +193.0K | May 15, 2026 |
| RTW Investments, LP | 12.87M | 9.60% | +1.44M | May 15, 2026 |
| Suvretta Capital Management, LLC | 11.19M | 8.34% | 0 | May 15, 2026 |
| Baker Bros. Advisors LP | 10.92M | 8.14% | −1.18M | May 15, 2026 |
| Perceptive Advisors LLC | 10.38M | 7.74% | 0 | May 29, 2026 |
| Toronto Dominion Bank | 7.44M | 5.55% | +7.44M | May 15, 2026 |
| Vestal Point Capital, LP | 6.18M | 4.60% | +50.0K | May 15, 2026 |
| Jefferies Financial Group Inc. | 5.06M | 3.77% | 0 | May 8, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.10% | 21.65M | 13G | May 15, 2026 ↗ |
| Baker Bros. Advisors LP | 9.95% | 12.09M | 13G | Nov 14, 2025 ↗ |
| RTW Investments, LP | 9.60% | 12.87M | 13G | May 15, 2026 ↗ |
| Suvretta Capital Management, LLC | 8.30% | 11.19M | 13G | Feb 13, 2026 ↗ |
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. | 7.90% | 9.47M | 13D/A | Oct 17, 2024 ↗ |
| The Toronto-Dominion Bank | 5.50% | 7.44M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | director | 11.25M | 8.39% | Aug 27, 2026 |
| Mathias Hothum | director | 329.5K | 0.25% | Mar 17, 2026 |
| Jasuja Harpreet Singh | director, officer: Chief Executive Officer | 217.2K | 0.16% | Mar 18, 2026 |
| Peter Alan Chambre | director | 106.0K | 0.08% | Mar 18, 2026 |
| Carsten Alexander Johannes Reinhardt | officer: Chief Development Officer | 47.8K | 0.04% | Mar 18, 2026 |
| Steffen Martin Walter | officer: Chief Operating Officer | 10.0K | 0.01% | Mar 18, 2026 |
| Jordan Zeik Silverstein | officer: Head of Strategy | 7.8K | 0.01% | Mar 18, 2026 |
| Cedrik Michael Britten | officer: Chief Medical Officer | 250 | 0.00% | Mar 18, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Perceptive Advisors LLCdirector | Purchase | 863,060 | $8.69 | 11,246,516 |
CongressHouse and Senate disclosures
Not reported.